May 03, 2019
Abraham Fruchter & Twersky LLP and Entwistle & Cappucci LLP have asked a Massachusetts federal judge to order Alere Inc. to pay $5.6 million in attorney fees as part of a $20 million settlement in a proposed class action in which investors claimed the company lied about its blood monitoring system.
February 01, 2019
Alere Inc. struck a $20 million deal with its investors to resolve claims that it allegedly lied about its blood-monitoring system and caused share price upheaval ahead of its proposed multibillion-dollar acquisition by Abbott Laboratories in 2016, according to a settlement proposed in Massachusetts federal court on Thursday.
July 02, 2018
Abbott Laboratories must check again for emails that a purported class of Alere Inc. investors believe will illustrate whether it lied about its blood-monitoring system and caused a stock-price rollercoaster leading up to the companies' multibillion-dollar merger in 2016, a Massachusetts federal judge ordered in court Monday.
April 19, 2018
Abbott Laboratories must relay four months' worth of merger discussions to a proposed class of Alere Inc. investors suing Alere over a dip in its stock price while the companies were negotiating a $5.3 billion merger in 2016, a federal magistrate judge ruled on Thursday in a Boston courtroom.
January 12, 2018
Abbott Laboratories must turn over documents related to its motive for balking at and then renegotiating its $5.3 billion purchase of Alere Inc., Alere investors said Thursday in Massachusetts federal court, arguing that Abbott's reasoning is key to their stock drop lawsuit against Alere.
August 23, 2017
Medical diagnostic equipment maker Alere Inc. won the dismissal of most of a securities fraud class action on Wednesday, with a Massachusetts federal judge concluding that there was little to support the idea that Alere's bosses knew about most of its alleged wrongdoing.
September 26, 2016
Shareholders in a proposed class action against Alere Inc. filed a consolidated complaint in Massachusetts federal court on Friday, accusing the company of withholding information about its internal controls and a federal probe into its dealings as it tried to push through a troubled $5.8 billion merger with Abbott Laboratories.